MedTrace Logo

ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study

NCT00745875 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2012-06-06

Study results available
· View outcomes & findings →

Summary

The aim of this study is to collect initial efficacy and safety data on the use of a new treatment ZD4054 (Zibotentan) when used in combination with pemetrexed (a standard chemotherapy agent) for the treatment of non-small cell lung cancer compared to treatment with pemetrexed alone

Conditions

Interventions

DRUG

ZD4054

10mg oral tablet, once daily

DRUG

Pemetrexed

500mg2/m IV infusion

DRUG

Placebo

10mg oral tablet, once daily

Sponsors & Collaborators

Principal Investigators

  • Thomas Morris, MD · AstraZeneca

  • Christos Chouaid, MD, Prof · Hospital Saint-Antoine, Cedex, France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • Bulgaria
  • Czechia
  • France
  • Romania
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00745875 on ClinicalTrials.gov